NOTCH1 and neoplasm: Activating mutations in NOTCH1 or loss of NUMB1, a negative regulator of NOTCH, occur in 10–30% of NSCLC patients (10), except in the squamous cell carcinoma subtype, where NOTCH mutations are usually inactivating and function as tumor suppressors (11).